{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T22:47:53Z","timestamp":1776638873197,"version":"3.51.2"},"reference-count":52,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.acvd.2013.06.055","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T15:31:34Z","timestamp":1380295894000},"page":"517-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects"],"prefix":"10.1016","volume":"106","author":[{"given":"Liu","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Jian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Changzhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Suihua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tang","family":"Wenyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2013.06.055_bib0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jacc.2007.10.002","article-title":"2007 focused update of the ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology\/American Heart Association Task Force on Practice guidelines","volume":"51","author":"King","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2005-869523","article-title":"Clopidogrel ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis","volume":"31","author":"Savi","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.acvd.2013.06.055_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2005.08.058","article-title":"Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance","volume":"47","author":"Lev","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0020","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0037-1613462","article-title":"Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement","volume":"89","author":"Muller","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2013.06.055_bib0025","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","article-title":"Resistance to clopidogrel: a review of the evidence","volume":"45","author":"Nguyen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0030","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0035","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2013.06.055_bib0040","first-page":"841","article-title":"Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis","volume":"103","author":"Sofi","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2013.06.055_bib0045","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1161\/01.ATV.0000223867.25324.1a","article-title":"Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel","volume":"26","author":"Angiolillo","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0050","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1538-7836.2009.03500.x","article-title":"The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome","volume":"7","author":"Frere","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2013.06.055_bib0055","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2013.06.055_bib0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/clpt.2008.20","article-title":"The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance","volume":"84","author":"Kim","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.acvd.2013.06.055_bib0065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jjcc.2010.10.007","article-title":"Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during anti-platelet therapy","volume":"57","author":"Yamamoto","year":"2011","journal-title":"J Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0070","first-page":"106","article-title":"Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease","volume":"7","author":"Akhlaghi","year":"2011","journal-title":"ARYA Atheroscler"},{"key":"10.1016\/j.acvd.2013.06.055_bib0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.acvd.2013.06.055_bib0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.thromres.2010.10.021","article-title":"The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention","volume":"127","author":"Hwang","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2013.06.055_bib0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000320093","article-title":"Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction","volume":"117","author":"Malek","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.acvd.2013.06.055_bib0090","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1253\/circj.CJ-12-0476","article-title":"Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in japanese patients receiving clopidogrel","volume":"76","author":"Nishio","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.acvd.2013.06.055_bib0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/hrt.2011.227272","article-title":"Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents","volume":"98","author":"Oh","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2013.06.055_bib0100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2012.12.028","article-title":"The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease","volume":"227","author":"Peng","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2013.06.055_bib0105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2013.06.055_bib0110","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00228-012-1446-8","article-title":"Effect of the CYP2C19 2 and 3 genotypes ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention","volume":"69","author":"Tang","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0115","first-page":"406","article-title":"Minimal clinically important differences: review of methods","volume":"28","author":"Wells","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0120","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.","author":"Wells","year":"2013"},{"key":"10.1016\/j.acvd.2013.06.055_bib0125","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1177\/147323001103900548","article-title":"Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel","volume":"39","author":"Luo","year":"2011","journal-title":"J Int Med Res"},{"key":"10.1016\/j.acvd.2013.06.055_bib0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1253\/circj.CJ-10-0525","article-title":"Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel","volume":"75","author":"Sawada","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.acvd.2013.06.055_bib0135","first-page":"617","article-title":"Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention","volume":"39","author":"Tang","year":"2011","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1016\/j.acvd.2013.06.055_bib0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2013.06.055_bib0145","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis","volume":"103","author":"Giusti","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0150","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/eurheartj\/ehq321","article-title":"CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study","volume":"31","author":"Harmsze","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2013.06.055_bib0155","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1253\/circj.72.1165","article-title":"Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel","volume":"72","author":"Malek","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.acvd.2013.06.055_bib0160","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2013.06.055_bib0165","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Pare","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2013.06.055_bib0170","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the anti-platelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2013.06.055_bib0175","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2013.06.055_bib0180","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ahj.2010.06.039","article-title":"Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events","volume":"160","author":"Tiroch","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2013.06.055_bib0185","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0190","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2013.06.055_bib0195","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.jacc.2007.11.080","article-title":"The role of aspirin in cardiovascular prevention: implications of aspirin resistance","volume":"51","author":"Gasparyan","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0200","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.acvd.2013.06.055_bib0205","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.amjcard.2012.04.020","article-title":"Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel","volume":"110","author":"Jang","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0210","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/hrt.2011.227652","article-title":"Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel","volume":"98","author":"Zabalza","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2013.06.055_bib0215","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s11033-010-0282-0","article-title":"Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel","volume":"38","author":"Jin","year":"2011","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.acvd.2013.06.055_bib0220","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis","volume":"56","author":"Hulot","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0225","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIR.0b013e3181ee08ed","article-title":"ACCF\/AHA Clopidogrel clinical alert: approaches to the FDA \u201cboxed warning\u201d: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association","volume":"122","author":"Holmes","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2013.06.055_bib0230","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/gm178","article-title":"Predictive, preventive, personalized and participatory medicine: back to the future","volume":"2","author":"Auffray","year":"2010","journal-title":"Genome Med"},{"key":"10.1016\/j.acvd.2013.06.055_bib0235","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.acvd.2010.05.001","article-title":"Clopidogrel resistance: what's new?","volume":"103","author":"Cuisset","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2013.06.055_bib0240","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"60","author":"Jneid","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0245","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2013.06.055_bib0250","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/eurheartj\/ehp157","article-title":"Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease","volume":"30","author":"Varenhorst","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2013.06.055_bib0255","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"Cannon","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2013.06.055_bib0260","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11894-013-0329-1","article-title":"Proton pump inhibitors and potential interactions with clopidogrel: an update","volume":"15","author":"Gerson","year":"2013","journal-title":"Curr Gastroenterol Rep"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213613002805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213613002805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:41:09Z","timestamp":1761745269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213613002805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1875213613002805"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2013.06.055","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2013.06.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}